Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn More
The most prevalent type of adult leukemia in Western populations is chronic lymphocytic leukemia (CLL). It is a lymphoproliferative disorder characterized by the expansion of a monoclonal population of mature CD5 CD23 B cells in the lymphoid tissues and bone marrow. Alfa Cytology is dedicated to the field of drug development in CLL, providing high-quality solutions to our clients.
Fig. 1. The cellular origin of chronic lymphocytic leukemia. (Bosch, F.; Dalla-Favera, R., 2019)
The genetic and epigenetic events underlying CLL development are believed to occur in HSCs, although this hypothesis remains controversial. Following the acquisition of genetic and epigenetic alterations in HSCs, the cellular output of these abnormalities may manifest as a polyclonal expansion of B-cell progenitors.
In 2022, the market size for CLL was $8.4 billion. The United States is the largest CLL market, accounting for over 70% of sales in major pharmaceutical markets including the US, France, Germany, Italy, Spain, the UK, and Japan. Currently, targeted therapies play a significant role in CLL therapy, contributing to the highest sales in the CLL market in 2022. Due to the increasing number of CLL patients and the continuous demand for innovative therapies, the global market for CLL therapy is projected to experience steady growth.
The powerful GVL effect of allogeneic HCT offers the potential for long-term remissions in an otherwise incurable malignancy. Unfortunately, the majority of patients are not suitable candidates for transplantation, and therefore, disease control and symptom management are primarily achieved through medication. There are three categories of drugs used for treating CLL, including chemotherapy agents, targeted therapies, and monoclonal antibodies.
Fig. 2. Timeline of approvals drugs for chronic lymphocytic leukemia. (Bosch, F.; Dalla-Favera, R., 2019)
After years of research, numerous drugs have been developed for CML therapy. The following table presents some medications used for CLL therapy.
| Drugs | Description |
|---|---|
| Bruton tyrosine kinase (BTK) inhibitors | Ibrutinib, a tyrosine kinase inhibitor (TKI), is employed for the management of symptomatic or progressive CLL that has recurred or proved refractory. Acalabrutinib, on the other hand, represents an alternative BTK inhibitor capable of enhancing progression-free survival. |
| BCL2 inhibitors | Venetoclax, a therapeutic agent targeting BCL2, exhibits a rapid reduction in CLL burden in lymph nodes and spleen. It has gained approval for patients with relapsed/refractory CLL accompanied by del(40p). |
| PI3K inhibitors | Idelalisib is indicated for patients who are intolerant to ibrutinib or experiencing their first relapse. |
| Monoclonal antibodies | They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Rituximab, ofatumumab, and obinutuzumab alone and in combination with chemotherapy are used to treat symptomatic or progressive, recurrent, or refractory CLL. |
The CLL therapy landscape has shifted from chemoimmunotherapies to targeted therapies. However, resistance mechanisms, including Richter's transformation, have emerged. There is an unmet need to discover new therapy strategies and molecular pathways for CLL cure. Below is a table of drugs currently in development.
| Drug | Phase | Target | Trial |
|---|---|---|---|
| Zanubrutinib (second-line or later monotherapy) | I | BTK | NCT02343120 |
| Zanubrutinib (first-line monotherapy [Arm C]) | III | BTK | NCT03336333 |
| Orelabrutinib (second-line or later monotherapy) | II | BTK | |
| Umbralisib (second-line or later monotherapy) | II | PI3K delta | NCT02742090 |
| Umbralisib (second-line or later combination therapy) | I | PI3K delta | NCT02006485 |
| ME-401 (second-line or later monotherapy or combination therapy) | I | PI3K | NCT02914938 |
| Venetoclax + obinutuzumab | III | BTK | NCT02264574 |
| Ibrutinib + obinutuzumab | III | BTK | NCT02242942 |
With the growing challenges of leukemia drug discovery and development, the need for integrated solutions has never been more evident. Models that employ traditional drug discovery are no longer adequate to address the complexity of cancer biology and therapy development effectively. Alfa Cytology's unwavering commitment to expertise and trust builds a strong partnership with you.
As an industry leader in the field of leukemia drug development, Alfa Cytology offers comprehensive research services to support your preclinical studies. Please contact us to learn more about our service offerings.
References